Casdin Capital’s DexCom DXCM Stock Holding History

Casdin Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-60,000	Closed	-$1.19M	–	29
2016 Q2	$1.19M	Buy	+60,000	New	+$1.02M	1.18%	25

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Casdin Capital's DXCM Position: Q1 2026 in Review

Casdin Capital sold out of DexCom (DXCM) in Q1 2026, closing a stake of 175,000 shares — an estimated $11.6M sold.

Casdin Capital first reported a position in DXCM in Q4 2015 and held it in 4 quarters. The position peaked at $11.6M in Q4 2025. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Casdin Capital reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
Casdin Capital sold 175,000 DexCom shares in Q1 2026, an estimated $11.6M.
Casdin Capital first reported a position in DexCom in Q4 2015 and held it in 4 quarters.
Casdin Capital's DexCom position peaked at $11.6M in Q4 2025.
957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.